What Is FGF4? Definition and What Research Reports
FGF4 (fibroblast growth factor 4) is a secreted signalling protein of the fibroblast growth factor family, encoded by the FGF4 gene and best known for its roles in embryonic development and tissue repair. It is a full-length growth factor rather than a short synthetic peptide. Published work is preclinical: researchers have reported effects of FGF4 in rodent models of fatty liver, immune-mediated liver injury, hyperglycaemia, cardiac injury and wound repair, alongside studies of FGF4 signalling in tumours and of FGF4 retrogenes in dogs.
Plain definition
FGF4, or fibroblast growth factor 4, is a secreted signalling protein belonging to the fibroblast growth factor (FGF) family. It is produced from the FGF4 gene, released by cells into the surrounding tissue, and acts locally by binding to fibroblast growth factor receptors (FGFRs) on nearby cells, which switches on intracellular signalling cascades that influence cell growth, differentiation, survival and metabolism. FGF4 is classically described as a developmental factor — it is active in the early embryo and in limb and skeletal patterning — but contemporary research describes it as a paracrine and endocrine-like regulator in adult organs such as the liver, heart, skin and brain. The term appears in genetics as well as in growth-factor pharmacology, because duplicated copies of the gene (retrogenes) shape body proportions in dogs.
What class of molecule is it?
FGF4 is a protein growth factor, not a short synthetic peptide. That distinction matters when the name turns up in peptide-related reading: molecules such as BPC-157 or GHK-Cu are short amino-acid chains, whereas FGF4 is a full-length, folded, secreted protein that requires heparan sulfate co-factors to engage its receptors. In the published literature FGF4 is handled as recombinant protein, as an engineered or non-mitogenic variant, as a gene-delivery payload, or — in one 2025 report — as protein encapsulated in cardiac-targeted nanoliposomes, an approach researchers used because delivery and tissue targeting are central problems for growth-factor proteins (Materials Today Bio, 2025).
Where it comes from
- Gene: the human FGF4 gene; expression is highest in embryonic tissues and is induced in certain adult tissues under stress.
- Receptors: FGF4 signals through FGF receptors; a 2025 study in Cell Metabolism described a hepatic FXR–FGF4 axis acting through an FGFR4–LRH-1 signal node in bile acid homeostasis under cholestatic stress (Cell Metabolism, 2025).
- Comparative genetics: in dogs, retrotransposed copies of the gene (FGF4 retrogenes) are inherited separately from the ancestral gene and have been linked to skeletal phenotypes, as reviewed in a 2022 analysis of canine morphology (Genes, 2022).
How the term is used in research
Three usages dominate. First, developmental and genetic: FGF4 as a patterning signal, and the canine FGF4 retrogenes as a natural experiment in skeletal biology. A 2020 report in Canine Medicine and Genetics examined foreleg abnormalities in Havanese dogs in the context of the FGF4 retrogene (Canine Medicine and Genetics, 2020). Second, metabolic and regenerative pharmacology: FGF4 administered to animals or cells as a candidate protective factor for liver, heart and skin. Third, oncology: FGF4 as a component of tumour signalling loops, where its growth-promoting activity is described as a liability rather than a benefit.
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeWhat the published literature reports
Liver and metabolism
The liver is the most heavily studied organ for FGF4. A 2022 study in Hepatology reported that FGF4 protected the liver from non-alcoholic fatty liver disease by activating an AMP-activated protein kinase–Caspase 6 signal axis (Hepatology, 2022). A 2024 paper in Acta Pharmaceutica Sinica B reported that FGF4 protected the liver from immune-mediated injury by activating the CaMKKβ–PINK1 pathway and inhibiting hepatocellular apoptosis (Acta Pharmaceutica Sinica B, 2024), and a separate 2024 report in the Journal of Translational Medicine described FGF4 ameliorating liver inflammation in experimental autoimmune hepatitis by reducing M1 macrophage polarisation (Journal of Translational Medicine, 2024). The bile-acid work cited above positioned hepatic FXR-driven FGF4 as a requirement for bile acid homeostasis under cholestatic stress (Cell Metabolism, 2025). On glucose handling, a 2023 Trends in Endocrinology and Metabolism piece summarised evidence that FGF4 alleviated hyperglycaemia in diabetes and obesity conditions (Trends in Endocrinology & Metabolism, 2023).
Heart, skin and nervous system
In cardiac work, researchers reported that cardiac-targeted FGF4-encapsulated nanoliposomes improved acute myocardial injury induced by ischaemia–reperfusion and by adriamycin in in vitro and in vivo models (Materials Today Bio, 2025). In skin, a 2023 study in the Journal of Investigative Dermatology reported that FGF4 promoted skin wound repair through p38 MAPK- and GSK3β-mediated stabilisation of the transcription factor Slug (Journal of Investigative Dermatology, 2023). In neuroscience, a 2024 paper in Neurobiology of Disease reported that TNFα prevented FGF4-mediated rescue of astrocyte dysfunction and reactivity in human ALS models — a result the authors framed as an inflammatory context limiting what FGF4 could do (Neurobiology of Disease, 2024).
Summary table
| Research area | Model type | What researchers reported |
|---|---|---|
| Fatty liver | Preclinical | Protection via AMPK–Caspase 6 axis (Hepatology, 2022) |
| Immune-mediated liver injury | Preclinical | Reduced hepatocellular apoptosis via CaMKKβ–PINK1 (Acta Pharm Sin B, 2024) |
| Autoimmune hepatitis | Experimental model | Less liver inflammation, reduced M1 macrophage polarisation (J Transl Med, 2024) |
| Glucose metabolism | Review of preclinical data | Alleviation of hyperglycaemia in diabetes and obesity conditions (Trends Endocrinol Metab, 2023) |
| Cardiac injury | In vitro and in vivo | Improvement of acute myocardial injury with targeted nanoliposomes (Mater Today Bio, 2025) |
| Skin wounds | Preclinical | Promoted repair via p38 MAPK and GSK3β–Slug (J Invest Dermatol, 2023) |
| Canine genetics | Observational | FGF4 retrogenes associated with skeletal morphology (Genes, 2022) |
Tumour biology and safety signals: What Studies Report
Because FGF–FGFR signalling drives proliferation, FGF4 also appears in cancer literature as a pro-tumour signal. A 2025 report in Cell Division described FGF4 driving tumour progression in triple-negative breast cancer via IL6/STAT3-mediated macrophage M2 polarisation and immune suppression (Cell Division, 2025). A 2025 study in Molecular Medicine reported that cancer-associated fibroblast-derived exosomes carrying GREM1 drove an FGF4/SHH feedback loop in non-small cell lung cancer (Molecular Medicine, 2025). In the ALS astrocyte work, the study reported that an inflammatory cytokine, TNFα, blocked the FGF4 effect entirely, illustrating that context determines outcome (Neurobiology of Disease, 2024). The canine literature adds a developmental caution: the 2020 Havanese report examined foreleg abnormalities in relation to the FGF4 retrogene (Canine Medicine and Genetics, 2020). None of these papers describe controlled human trials of FGF4 administration, and no human safety dataset is summarised here because the verified literature does not contain one.
Tracking research? Log entries with dates, lots and notes — records, never plans.
Get the appLimits of the evidence
- The protective findings above come from cell systems and animal models; they are not human clinical outcomes.
- Delivery is unresolved — the cardiac study used an engineered nanoliposome formulation specifically to target tissue (Materials Today Bio, 2025).
- The same signalling that researchers reported as protective in liver and skin is reported as tumour-promoting in breast and lung cancer models (Cell Division, 2025).
- Genetic evidence in dogs concerns inherited retrogene copies, not administered protein (Genes, 2022).
This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question or before making any decision involving an investigational compound. FGF4 as described in the cited literature is a research subject, and the material above summarises what published studies reported rather than any suggested application.
References
- FGF4 protects the liver from nonalcoholic fatty liver disease by activating the AMP-activated protein kinase-Caspase 6 signal axis (Hepatology, 2022)
- FGF4 protects the liver from immune-mediated injury by activating CaMKKβ-PINK1 signal pathway to inhibit hepatocellular apoptosis (Acta Pharmaceutica Sinica B, 2024)
- FGF4 ameliorates the liver inflammation by reducing M1 macrophage polarization in experimental autoimmune hepatitis (Journal of Translational Medicine, 2024)
- Hepatic FXR-FGF4 is required for bile acid homeostasis via an FGFR4-LRH-1 signal node under cholestatic stress (Cell Metabolism, 2025)
- FGF4 alleviates hyperglycemia in diabetes and obesity conditions (Trends in Endocrinology and Metabolism, 2023)
- Cardiac-targeted FGF4 encapsulated nanoliposomes improve acute myocardial injury induced by ischemia-reperfusion and adriamycin in in vitro and in vivo models (Materials Today Bio, 2025)
- FGF4 Promotes Skin Wound Repair through p38 MAPK and GSK3β-Mediated Stabilization of Slug (Journal of Investigative Dermatology, 2023)
- TNFα prevents FGF4-mediated rescue of astrocyte dysfunction and reactivity in human ALS models (Neurobiology of Disease, 2024)
- FGF4 drives tumor progression in triple-negative breast cancer via IL6/STAT3-mediated macrophage M2 polarization and immune suppression (Cell Division, 2025)
- CAF-derived exosomes drive the FGF4/SHH feedback loop by encapsulating GREM1 in non-small cell lung cancer (Molecular Medicine, 2025)
- The Effects of FGF4 Retrogenes on Canine Morphology (Genes, 2022)
- Short and sweet: foreleg abnormalities in Havanese and the role of the FGF4 retrogene (Canine Medicine and Genetics, 2020)
Frequently asked questions
What does FGF4 stand for?▾
FGF4 stands for fibroblast growth factor 4, a secreted signalling protein in the fibroblast growth factor family encoded by the FGF4 gene. It acts by binding fibroblast growth factor receptors on nearby cells. One study described a hepatic FXR–FGF4 axis signalling through an FGFR4–LRH-1 node in bile acid homeostasis under cholestatic stress (PMID 39393353).
Is FGF4 a peptide?▾
Not in the sense that term is usually used. FGF4 is a full-length, folded, secreted growth-factor protein rather than a short synthetic amino-acid chain. Researchers work with it as recombinant protein or engineered formulations; one 2025 report used cardiac-targeted nanoliposomes to encapsulate FGF4 in myocardial injury models, reflecting the delivery challenges of protein-sized molecules (PMID 40677395).
What has research reported about FGF4 and the liver?▾
Preclinical liver work dominates the literature. Researchers reported protection against non-alcoholic fatty liver disease through an AMPK–Caspase 6 axis (PMID 35152446), protection from immune-mediated injury via CaMKKβ–PINK1 signalling that inhibited hepatocellular apoptosis (PMID 38572102), and reduced liver inflammation with less M1 macrophage polarisation in experimental autoimmune hepatitis (PMID 39095789). These were animal and cell models, not human trials.
Why is FGF4 discussed in dog genetics?▾
Dogs carry retrotransposed copies of the FGF4 gene, called FGF4 retrogenes, which are inherited independently of the original gene. A 2022 analysis examined how these retrogenes relate to canine morphology (PMID 35205370), and a 2020 report described foreleg abnormalities in Havanese dogs in the context of the FGF4 retrogene (PMID 33372642).
Has FGF4 been studied in cancer?▾
Yes, and in that setting the signalling is described as harmful rather than protective. A 2025 study reported FGF4 driving triple-negative breast cancer progression via IL6/STAT3-mediated macrophage M2 polarisation and immune suppression (PMID 41039618). Another reported that cancer-associated fibroblast exosomes carrying GREM1 drove an FGF4/SHH feedback loop in non-small cell lung cancer (PMID 40849639).
What did studies report about FGF4 in metabolic and nervous system models?▾
A 2023 review summarised evidence that FGF4 alleviated hyperglycaemia in diabetes and obesity conditions in preclinical settings (PMID 37625920). In neuroscience, a 2024 study reported that the inflammatory cytokine TNFα prevented FGF4-mediated rescue of astrocyte dysfunction and reactivity in human ALS models, indicating that the surrounding inflammatory context altered the outcome (PMID 39362568).
Is there human clinical evidence for FGF4?▾
The verified literature summarised on this page consists of cell-based studies, animal models, a mechanistic review and comparative genetics reports. For example, skin wound repair findings came from preclinical work describing p38 MAPK and GSK3β-mediated stabilisation of Slug (PMID 36521556). No controlled human trial of administered FGF4 is described in these sources. This page is educational and not medical advice.
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.